CTOs on the Move

Nipro Medical

www.nipro.com

 
Nipro provides premium renal medical devices, including dialyzers, bloodlines, AVF needles, as well as high-quality medical surgical products.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.nipro.com
  • 200, Crossing Blvd
    Bridgewater, NJ USA 08807
  • Phone: 908.393.7030

Executives

Name Title Contact Details

Similar Companies

Highland Therapeutics

Highland Therapeutics Inc., a Toronto-based specialty pharmaceutical company. It is a specialty pharmaceutical company leveraging its proprietary technologies to optimize the delivery of previously approved drug products.

TYRX

TYRX is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Infinity Care Solutions

Infinity Care Solutions wants to take the time and trouble out of a normal pharmacy experience by not only providing you with traditional medications, but also offering you and your healthcare provider a choice. We know that no two patients are exactly the same and each requires specific knowledge and a team approach. It is our goal to meet this challenge head on. With our top-of-the-line, custom-made compounded products, and our impeccable customer service, our mission is for you to experience symptom relief like never before. Our pharmacy is built on a solid foundation of medical expertise and cutting edge pharmaceutical compounding methods that are unmatched, especially in the areas of topical hormone replacement therapy and topical pain medications.

Sarnova

Sarnova is the leading national specialty distributor of healthcare products in the emergency medical services (EMS) and acute care markets. The company is comprised of four major business units: Bound Tree Medical, DXE Medical, Emergency Medical ...

Milestone Pharmaceuticals

Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.